BOUCHERVILLE, QC--(Marketwired - February 04, 2016) - Sandoz Canada Inc., a Novartis company, continues to expand its cancer medication portfolio with the recent launch of PrOxaliplatin Injection, which is given along with other medicines to treat advanced colon cancer.
PrOxaliplatin Injection is a generic equivalent to PrEloxatin*. It belongs to a group of medicines called antineoplastics that helps inhibit the replication process of cancer cells.
“This latest product launch demonstrates that Sandoz Canada is becoming an important player in the field of generic cancer medications,” says Michel Robidoux, President and General Manager of Sandoz Canada.
In combination with infusional 5-fluorouracil/leucovorin (5-FU/LV), PrOxaliplatin Injection is indicated for adjuvant treatment of patients with stage III (Dukes’ C) colon cancer after a complete resection of the primary tumour. In addition, it is also indicated for the treatment of patients with metastatic colorectal cancer.
Each vial contains 100 mg, 150 mg or 200 mg of oxaliplatin as a sterile, preservative free, aqueous solution at a concentration of 5 mg/mL.
The launch of PrOxaliplatin Injection is an integral part of our overall strategy for addressing global access challenges that combines our broad portfolio of off-patent, added value medicines with novel services and corporate responsibility programs to improve access to medicines, medical information and medical capacity building.
The company’s other cancer drugs include methotrexate, cisplatin, topotecan, gemcitabine, paclitaxel, doxorubicin, etoposide, letrozole, anastrozole, 5-FU, and other related products such as ondansetron and zoledronic acid-Z.